Financing ·
Senti Biosciences secures $4.55M equity commitment from Celadon affiliate
SNTISenti Biosciences Holdings, Inc.
Senti Biosciences Holdings entered into an equity commitment letter with CPIF II-9 Limited, an entity affiliated with Celadon Partners SPV 24 Limited, to purchase up to $4.55 million of common stock at the Nasdaq Minimum Price. The funding is scheduled quarterly: $1.8 million by December 31, 2026; $1.35 million by March 31, 2027; and remaining tranches totaling $1.4 million through December 31, 2027. The agreement includes customary registration rights for the investor. Senti Biosciences is a biotechnology company developing gene-editing therapies.